FLI1 Promotes IFN-γ-induced Kynurenine Production to Impair Anti-tumor Immunity
Overview
Authors
Affiliations
Nasopharyngeal carcinoma (NPC)-mediated immunosuppression within the tumor microenvironment (TME) frequently culminates in the failure of otherwise promising immunotherapies. In this study, we identify tumor-intrinsic FLI1 as a critical mediator in impairing T cell anti-tumor immunity. A mechanistic inquiry reveals that FLI1 orchestrates the expression of CBP and STAT1, facilitating chromatin accessibility and transcriptional activation of IDO1 in response to T cell-released IFN-γ. This regulatory cascade ultimately leads to augmented IDO1 expression, resulting in heightened synthesis of kynurenine (Kyn) in tumor cells. This, in turn, fosters CD8 T cell exhaustion and regulatory T cell (Treg) differentiation. Intriguingly, we find that pharmacological inhibition of FLI1 effectively obstructs the CBP/STAT1-IDO1-Kyn axis, thereby invigorating both spontaneous and checkpoint therapy-induced immune responses, culminating in enhanced tumor eradication. In conclusion, our findings delineate FLI1-mediated Kyn metabolism as an immune evasion mechanism in NPC, furnishing valuable insights into potential therapeutic interventions.
Zhang M, Wan L, Fang H, Zhang X, Wang S, Li F J Inflamm Res. 2025; 18:3105-3123.
PMID: 40059948 PMC: 11889415. DOI: 10.2147/JIR.S507941.
Methionine metabolite spermidine inhibits tumor pyroptosis by enhancing MYO6-mediated endocytosis.
Wu J, Ding C, Zhang C, Xu Z, Deng Z, Wei H Nat Commun. 2025; 16(1):2184.
PMID: 40038267 PMC: 11880502. DOI: 10.1038/s41467-025-57511-4.
Fatty acid metabolism: A new target for nasopharyngeal carcinoma therapy.
Li J, Ping P, Li Y, Xu X Chin J Cancer Res. 2025; 36(6):652-668.
PMID: 39802901 PMC: 11724175. DOI: 10.21147/j.issn.1000-9604.2024.06.05.
Yu K, Tang Y, Wang C, Liu W, Hu M, Hu A Int J Mol Sci. 2025; 25(24.
PMID: 39769192 PMC: 11676164. DOI: 10.3390/ijms252413426.
Future investigative directions for novel therapeutic targets in head and neck cancer.
Nguyen J, Woerner L, Johnson D, Grandis J Expert Rev Anticancer Ther. 2024; 24(11):1067-1084.
PMID: 39412140 PMC: 11514385. DOI: 10.1080/14737140.2024.2417038.